KALV
KalVista Pharmaceuticals, Inc. NASDAQ Listed Apr 9, 2015$26.72
Mkt Cap $1.4B
52w Low $9.83
99.3% of range
52w High $26.84
50d MA $19.25
200d MA $15.23
P/E (TTM)
-7.2x
EV/EBITDA
-3.4x
P/B
13.9x
Debt/Equity
0.1x
ROE
-1065.3%
P/FCF
-4.5x
RSI (14)
—
ATR (14)
—
Beta
-0.40
50d MA
$19.25
200d MA
$15.23
Avg Volume
983.9K
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
55 Cambridge Parkway · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 26.72 | +0.0% | +0.0% | — | — | — | — | — |
| May 5, 2026 | BMO | -0.38 | -0.92 | -144.5% | 26.66 | +0.0% | +0.2% | +0.2% | +0.2% | — | — | — |
| Mar 24, 2026 | BMO | -0.54 | -1.01 | -87.0% | 16.46 | +4.3% | +4.1% | +4.1% | +15.1% | +17.4% | +11.5% | — |
| Nov 10, 2025 | BMO | -0.96 | -0.92 | +4.2% | 10.89 | +4.6% | +5.3% | +5.3% | +22.5% | +20.2% | +25.1% | — |
| Sep 11, 2025 | BMO | -0.91 | -1.12 | -23.1% | 14.81 | -1.4% | -5.4% | -5.4% | -8.0% | -8.8% | -9.7% | — |
| Jul 10, 2025 | BMO | -0.77 | -0.99 | -28.6% | 15.51 | -4.1% | -6.4% | -6.4% | -1.9% | -2.2% | +1.8% | — |
| Mar 12, 2025 | BMO | -0.89 | -0.92 | -3.4% | 12.45 | -0.8% | -1.6% | -1.6% | +1.2% | +0.3% | -0.6% | — |
| Dec 5, 2024 | BMO | -0.91 | -0.91 | +0.0% | 9.06 | -0.7% | +8.3% | +8.3% | +3.1% | +4.2% | +0.3% | — |
| Sep 5, 2024 | BMO | -0.91 | -0.87 | +4.4% | 12.87 | +2.1% | -4.1% | -4.1% | -7.8% | -12.9% | -16.7% | — |
| Jul 11, 2024 | BMO | -0.73 | -1.02 | -39.7% | 12.50 | +1.0% | +4.3% | +4.3% | +19.7% | +22.0% | +19.8% | — |
| Mar 11, 2024 | BMO | -0.77 | -0.84 | -9.1% | 13.10 | -1.8% | -4.7% | -4.7% | -4.7% | -5.1% | -8.9% | — |
| Dec 7, 2023 | BMO | -0.79 | -0.80 | -1.3% | 8.97 | -0.8% | -9.0% | -9.0% | -2.0% | +8.8% | +10.4% | — |
| Sep 7, 2023 | BMO | -0.86 | -0.74 | +14.0% | 10.84 | +0.9% | -4.5% | -4.5% | -2.8% | -4.8% | -6.9% | — |
| Jul 7, 2023 | AMC | -0.92 | -0.77 | +16.3% | 10.29 | +1.2% | +1.7% | -4.8% | -6.4% | -5.2% | -6.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | H.C. Wainwright | Downgrade | Buy → Neutral | $27 | $26.66 | $26.66 | +0.0% | -0.0% | +0.0% | +0.2% | +0.2% | +0.2% |
| Mar 26 | Stifel | Maintains | Buy → Buy | — | $17.14 | $16.97 | -1.0% | +10.6% | +12.8% | +7.1% | +17.4% | +15.3% |
| Mar 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $17.14 | $16.97 | -1.0% | +10.6% | +12.8% | +7.1% | +17.4% | +15.3% |
| Mar 25 | Needham | Maintains | Buy → Buy | — | $16.46 | $17.17 | +4.3% | +4.1% | +15.1% | +17.4% | +11.5% | +22.3% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $15.82 | $18.60 | +17.6% | +6.2% | +3.6% | -5.6% | -3.7% | -5.4% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.82 | $18.60 | +17.6% | +6.2% | +3.6% | -5.6% | -3.7% | -5.4% |
| Jan 6 | Needham | Maintains | Buy → Buy | — | $15.66 | $15.96 | +1.9% | +0.6% | +4.3% | +1.0% | +7.3% | +4.7% |
| Dec 4 | Needham | Maintains | Buy → Buy | — | $14.66 | $14.63 | -0.2% | +11.9% | +12.1% | +15.0% | +10.2% | +15.0% |
| Nov 11 | Citizens | Maintains | Market Outperform → Market Outperform | — | $10.89 | $11.39 | +4.6% | +5.3% | +22.5% | +20.2% | +25.1% | +36.5% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $14.81 | $14.61 | -1.4% | -5.4% | -8.0% | -8.8% | -9.7% | -6.3% |
| Sep 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.81 | $14.61 | -1.4% | -5.4% | -8.0% | -8.8% | -9.7% | -6.3% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.51 | $14.88 | -4.1% | -6.4% | -1.9% | -2.2% | +1.8% | +3.2% |
| Jul 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $15.06 | $15.43 | +2.5% | -0.7% | +6.2% | +3.0% | -3.6% | +1.1% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.06 | $15.43 | +2.5% | -0.7% | +6.2% | +3.0% | -3.6% | +1.1% |
| Jul 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $11.98 | $14.02 | +17.0% | +25.7% | +24.8% | +33.5% | +29.5% | +21.2% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $11.50 | $11.56 | +0.5% | -10.3% | -5.9% | -8.3% | -0.1% | +3.9% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $12.50 | $12.32 | -1.4% | -3.4% | -1.3% | -4.6% | -7.7% | -10.7% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $12.50 | $12.32 | -1.4% | -3.4% | -1.3% | -4.6% | -7.7% | -10.7% |
| Mar 26 | Jones Trading | Maintains | Buy → Buy | — | $12.50 | $12.32 | -1.4% | -3.4% | -1.3% | -4.6% | -7.7% | -10.7% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.25 | $12.25 | +0.0% | +2.9% | +2.0% | +1.0% | -1.2% | -2.0% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $12.45 | $12.35 | -0.8% | -1.6% | +1.2% | +0.3% | -0.6% | -2.8% |
| Mar 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $11.40 | $11.51 | +1.0% | -4.6% | -1.1% | +1.8% | +5.1% | +4.6% |
| Dec 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.81 | $9.75 | -0.6% | -4.8% | -3.8% | -7.3% | -10.9% | -11.4% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.06 | $9.00 | -0.7% | +8.3% | +3.1% | +4.2% | +0.3% | -3.5% |
| Dec 5 | Needham | Maintains | Buy → Buy | — | $9.46 | $9.69 | +2.4% | -4.2% | +3.7% | -1.3% | -0.2% | -3.9% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.36 | $11.27 | -0.8% | -0.7% | -1.3% | -1.1% | -3.3% | +2.4% |
| Sep 6 | Needham | Maintains | Buy → Buy | — | $12.87 | $13.14 | +2.1% | -4.1% | -7.8% | -12.9% | -16.7% | -18.7% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.87 | $13.14 | +2.1% | -4.1% | -7.8% | -12.9% | -16.7% | -18.7% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.04 | $13.18 | +1.1% | +14.7% | +16.9% | +14.8% | +8.9% | +11.6% |
| Jul 12 | Needham | Maintains | Buy → Buy | — | $12.50 | $12.63 | +1.0% | +4.3% | +19.7% | +22.0% | +19.8% | +13.6% |
| Jun 18 | Needham | Maintains | Buy → Buy | — | $11.82 | $11.77 | -0.4% | -3.8% | -5.2% | -0.7% | -0.8% | -2.3% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.17 | $12.24 | +0.6% | -0.3% | -0.2% | +0.2% | -0.9% | -0.7% |
| May 1 | Needham | Maintains | Buy → Buy | — | $11.35 | $11.35 | +0.0% | +7.3% | +7.2% | +6.9% | +7.0% | +7.4% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $11.93 | $11.87 | -0.5% | +1.4% | -0.3% | -1.6% | -0.4% | -2.3% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.10 | $12.86 | -1.8% | -4.7% | -4.7% | -5.1% | -8.9% | -8.5% |
| Mar 11 | Needham | Maintains | Buy → Buy | — | $14.36 | $14.04 | -2.2% | -8.8% | -13.0% | -13.0% | -13.4% | -16.9% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.85 | $14.95 | +0.7% | -3.0% | -0.6% | +0.1% | -7.1% | -12.2% |
| Feb 13 | Needham | Maintains | Buy → Buy | — | $16.04 | $15.84 | -1.2% | -7.4% | -10.2% | -8.0% | -7.4% | -14.0% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.84 | $10.94 | +0.9% | -4.5% | -2.8% | -4.8% | -6.9% | -8.0% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.97 | $10.97 | +0.0% | +0.3% | -0.4% | -3.3% | +0.1% | -1.4% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.29 | $10.41 | +1.2% | +1.7% | -4.8% | -6.4% | -5.2% | -6.3% |
| Mar 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.35 | $7.49 | +1.9% | -5.3% | +1.9% | +4.4% | +1.4% | +1.4% |
| Feb 3 | SVB Leerink | Maintains | Outperform → Outperform | — | $7.62 | $7.54 | -1.0% | +3.3% | +5.9% | +9.3% | +4.1% | +0.7% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.17 | +0.4% | -4.3% | -3.9% | -8.9% | -10.5% | -12.0% |
| Oct 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.85 | $5.87 | +0.3% | -12.0% | -15.7% | -15.4% | -19.8% | -21.2% |
| Oct 4 | Needham | Maintains | Buy → Buy | — | $14.24 | $6.99 | -50.9% | -58.9% | -63.8% | -65.4% | -65.2% | -67.1% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $10.98 | $10.69 | -2.6% | +0.8% | -3.6% | +7.6% | +13.2% | +9.7% |
| Jul 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $10.98 | $10.69 | -2.6% | +0.8% | -3.6% | +7.6% | +13.2% | +9.7% |
| Jun 8 | Stifel | Maintains | Buy → Buy | — | $8.85 | $8.73 | -1.4% | -5.1% | -3.4% | -5.6% | -7.8% | -5.3% |
| Mar 11 | Needham | Maintains | Buy → Buy | — | $16.38 | $16.30 | -0.5% | -6.0% | -12.2% | -11.5% | -11.8% | -6.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.
Apr 20
8-K
Unknown — 8-K Filing
KalVista's eight-month financial results and corporate update suggest material business developments; investors should review cash position, pipeline progress, and any strategic announcements that could significantly impact the biotech company's runway and stock valuation.
Mar 25
Data updated apr 25, 2026 5:11pm
· Source: massive.com